Anifrolumab treatment of Singleton-Merten syndrome 2 due to a novel RIGI variant
- PMID: 40913606
- DOI: 10.1016/j.jaci.2025.08.001
Anifrolumab treatment of Singleton-Merten syndrome 2 due to a novel RIGI variant
Keywords: RIG-I/RIGI; Singleton-Merten syndrome; anifrolumab; type I interferons.
Conflict of interest statement
Disclosure statement Supported by the National Research Science Award T32 program (grant 232A1007512-38 [to M.T.L.]), the Brigham and Women’s Department of Medicine and the Rheumatology Fellowship Training Program (to C.A.R.), the Samara Jan Turkel Clinical Center for Pediatric Autoimmune Disease (to M.B.S.), the Rheumatology Research Foundation R Bridge Award and Innovative Research Award (to P.Y.L.), and the Boston Children’s Hospital Translational Research Program Pilot Award (to P.Y.L.). Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
Publication types
LinkOut - more resources
Full Text Sources